inflammation/lafyèv

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 590 rezilta yo

N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has

Complementary Intervention for COVID-19

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Since last December 2019, a syndrome of severe pneumonia associated with the coronavirus disease 2019 (COVID-19) emerged in Wuhan, Hubei Province, China. It is highly contagious and rapidly spread to many other parts of China and almost all countries all over the world, representing one of the most

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Ta1 is a naturally occurring peptide that has been evaluated for its immunomodulatory activities and related therapeutic potential in several conditions and diseases, including infectious disease and cancer. ZADAXIN® brand Ta1 is a synthetic version currently approved for use in 37 countries; in

Suloexide in the Treatment of Early Stages of COVID-19

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Objective: To use sulodexide in patients that have early onset of COVID-19 symptoms to mitigate the progression of the disease process that can allow them to recover at home, and limit the need for hospital care and the more severe manifestation which includes fulminant respiratory failure, acute

Therapeutic Plasma Exchange (TPE) for Covid-19 Cytokine Release Storm (CRS)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PROTOCOL SUMMARY: Long title: Proposed use of TPE (therapeutic plasma exchange), to Limit Coronavirus Associated Complications: An Open label, Phase 2 Study Clinical Phase: Two arms, Phase 2 Open Label Conducted by: Department of Pulmonology and Critical Care; Pak Emirates Military Hospital. Sample

Characterization of a Functional Test for Mediterranean Family Fever Screening - 2

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Obesity Surgery During 2020 Italian Pandemic

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . The disease was first identified in December 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Clinical Design. Eligible healthcare workers (HCW) or first responders in the greater New Orleans area (n=60) meeting eligibility criteria will be enrolled into a 12 month study by the Louisiana State University Health Sciences Center Clinical & Translational Research Center (LSUHSC CTRC) clinical

Role of Montelukast in Modulation of Response to Sepsis in Preterm Infants

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Since inflammatory mediators play a crucial role in the pathophysiology of sepsis so anti-inflammatory treatment, Montelukast, could be a beneficial therapy. The investigators will conduct this pilot, open-labeled, randomized controlled intervention trial on 40 newborns admitted to NICU. The study

Role of Co-trimoxazole in Severe COVID-19 Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Coronavirus disease (COVID-19) caused by SARS-COV2, represents a highly transmissible and potentially fatal disease that is of great global public health concern at this moment. The pandemic situation in Bangladesh is also evolving rapidly with positive cases and deaths increasing each day.

Investigation of Safety and Efficacy of CARDIO Softgels in Former Smokers and Asthma Patients With COVID-19 Infection

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

SARS-CoV-2, a plus-sense single-stranded RNA virus, is the etiologic agent of COVID-19. After an incubation period, which typically lasts for 5-6 days, COVID-19 patients present with a mild illness that lasts for a few days. Common symptoms are reminiscent of the flu, and include fever, dry cough

Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Introduction Coronavirus disease 2019 (CoViD-19) is a new pathogen that is highly contagious, can spread quickly, and it is capable of causing enormous health, economic and societal impacts in any setting (WHO-China joint mission on CoViD-19). Although COVID 19 belongs to coronavirinae sub-family

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Efficacy and Safety of Sirolimus in COVID-19 Infection

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In early December 2019, several pneumonia cases of unknown origin were observed in Wuhan (China). A novel enveloped RNA β coronavirus was isolated and named severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2). The new virus rapidly spread across China and worldwide. On March 11th 2020, the

CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The present study will be a single-center, randomized, parallel, double-blind, placebo-controlled clinical trial of CBD in patients with mild to moderate SARS-CoV-2 infection. The investigators will use random stratification by minimizing the sample to stratify all eligible patients according to

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye